Everything Editor: Bi Luming
A shares are approaching the end of the year, and the goodwill of listed companies has exploded again!
htmlOn the evening of January 3, Zhongsheng Pharmaceutical (002317, SZ) announced that it is expected to lose 380 million to 450 million yuan in 2020, and make a profit of 3.2 yuan in the same period last year. It plans to set aside 740 million yuan to 780 million yuan, 80 million yuan to 100 million yuan and 8.92 million yuan respectively. This also means that the company will set aside a maximum of 888.9 million yuan in goodwill impairment.
Judging from the recent stock price trend, Zhongsheng Pharmaceutical is not synchronized with the market index, and it shows a weak trend. The latest market value is less than 9 billion yuan. This week, it closed continuously and pulled significantly, from 18.56 yuan/share at the high of July 14, 2020 to 10.8 yuan/share on December 28, fell by 45% in the half-year. As of the latest closing data of , Zhongsheng Pharmaceutical was 11.02 yuan per share, up 0.09%, with a turnover of only 89.73 million yuan.
As of September 30, 2020, the number of A-share accounts in this stock was 34,300, a decrease of 2,000 on a month-on-month basis.
In response to this, stock bar netizens have left messages, and some netizens in said, "Tomorrow's limit down will increase positions"; "As a matter of fact, there is lightning, retail investors will always go one step later."
According to public information, Zhongsheng Pharmaceutical is a high-tech enterprise integrating drug research and development, production and marketing. Its current main business is the research and development, production and sales of traditional Chinese patent medicines, chemical medicines, Chinese medicinal materials and Chinese herbal medicines, chemical raw materials, as well as investment in ophthalmology-related industries. The main products cover major diseases such as ophthalmology, cardiovascular and cerebrovascular, respiratory, digestive and senile degenerative lesions.
is expected to set aside a maximum of about 889 million goodwill impairment
Zhongsheng Pharmaceutical said that the company's wholly-owned subsidiary Guangdong Xianqiang Pharmaceutical Co., Ltd. (hereinafter referred to as "Xianqiang Pharmaceutical")'s main products are adenosine monophosphate monophosphate and cefixime dispersed tablets. Due to the impact of the epidemic in the first half of the year, sales fell sharply. Although they recovered under active marketing strategies in the second half of the year, they still failed to get rid of the impact of the epidemic by the end of the year, and sales for the whole year decreased significantly. At present, the national health protection awareness has been strengthened comprehensively. It is expected that the demand for drugs in related fields will continue to remain low in the short and medium term. At the same time, some varieties of Xianqiang Pharmaceuticals are facing pressure from national centralized procurement, and it is difficult to achieve the expected sales level in the long run. According to regulations, the company plans to set aside goodwill impairment provisions ranging from RMB 740 million to RMB 780 million. After this goodwill impairment, Xianqiang Pharmaceutical's goodwill balance ranges from RMB 95.35 million to RMB 135.35 million.
Yishu Pharmaceutical's performance was also affected by the epidemic. Zhongsheng Pharmaceutical said that in view of the difficulty of technology development and changes in the market environment, the company recently decided to terminate the research on the consistency evaluation of generic drugs for the main products omeprazole enteric-coated capsules and other products. According to regulations, the company plans to set aside goodwill impairment provisions ranging from RMB 80 million to RMB 100 million. After this goodwill impairment, Yishu Pharmaceutical's goodwill balance ranges from RMB 62.67 million to RMB 82.67 million.
Zhongsheng Pharmaceutical said that the company's wholly-owned subsidiary Guangzhou Tangwang Medical Technology Co., Ltd.'s business was basically suspended due to the impact of the epidemic in the first half of the year, the team lost serious personnel, and market-oriented operations were difficult. The company recently re-planned the company's development path and determined its strategic positioning to use it as a supporting means for the company's retail and grassroots marketing business. In accordance with the provisions of "Enterprise Accounting Standard No. 8 - Asset Impairment" and relevant accounting policies, the company plans to fully set aside 8.92 million yuan in goodwill impairment provisions.
In addition, the company's net profit after deducting the above-mentioned goodwill impairment has increased compared with the same period. On the one hand, the company's core variety is chronic disease medication. With the effective control of the domestic epidemic, terminal demand has been recovered well, and the market sales of the company's main products have gradually returned to normal in the second half of the year. Faced with changes in the market environment and the impact of the epidemic, the company actively faced it and continued to implement the marketing strategy of "full products, all terminals, and all channels", and increased efforts to cover the retail, county and primary medical markets, so that the contribution of various business segments is more stable. On the other hand, the disposal of the subsidiary's equity recognition income has led to an increase in investment income, and it is expected that the impact of non-recurring gains and losses on the company's net profit will be approximately RMB 220 million.
is adding another subsidiary,
On December 16, 2020, Zhongsheng Pharmaceutical issued an announcement stating that the board of directors passed the "Proposal on Capital Increase and Share Expansion and Related Transactions of the Company's Holding Subsidiaries". In order to supplement the funds for innovative drug research and development projects, promote the company's development and the process of innovative drug research and development projects, the company's controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang") plans to introduce investors through cash capital increase, with an additional registered capital of RMB 15 million. The company invested RMB 30 million with its own funds and subscribed the newly registered capital of RMB 1.6236 million, which was included in the capital reserve of Zhongsheng Ruichuang.
public information shows that Zhongsheng Pharmaceutical invested in the establishment of holding subsidiary Zhongsheng Ruichuang with five innovative drug projects, namely ZSP1601, ZSYM007 and ZSYM008 in the liver disease field and ZSP1603 and ZSP1273 in the respiratory field, and successfully introduced the first round A strategic investors and introduced US$15.8 million in external funds. On October 23, 2018, Zhongsheng Ruichuang completed the industrial and commercial registration procedures, with a registered capital of RMB 100 million, of which Zhongsheng Pharmaceutical holds 92.50% of Zhongsheng Ruichuang, Ruichuang Pharmaceutical holds 7.00% of Zhongsheng Ruichuang, and Zhou Xueli holds 0.50% of the equity.
Daily Economic News integrates the announcements, public information, stock bar
(The article published by the Meijing App for the purpose of conveying more information does not mean that it agrees with its views or confirms its description. The content or data of the article is for reference only and does not constitute investment advice. Investors act on this basis at their own risk.)
Daily Economic News
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-